Kayothera
  • Science
  • Team
  • Investors
  • News
  • Contact
Select Page
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes

The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes

Aug 12, 2024 | News

Review | Cancer Focus| August 12 2024 In Special Collection: Mechanisms and Models of Cancer 2024 Mark Esposito, John K. Amory, Yibin Kang J Exp Med (2024) 221 (9): e20240519. https://doi.org/10.1084/jem.20240519
Join us at BioNJ BioPartnering

Join us at BioNJ BioPartnering

Apr 3, 2024 | Events, News

Join our Co-Founder Dr. Mark Esposito as he shares an update on Kayothera at BioNJ BioPartnering on May 14th.
Join us at BioNJ BioPartnering

Join us at Life Science Innovation Northwest 2024

Apr 3, 2024 | Events, News

Join our Co-Founder Dr. Mark Esposito as he shares an update on Kayothera at Life Science Innovation Northwest (LSINW) 2024 on April 18th at 11:05 AM – 12:15 PM.
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

Sep 18, 2023 | News, Press Release

 Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies  Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024 Seattle, WA —...
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes

Washington state backs AI-driven cancer diagnostics and other startup projects

Aug 11, 2023 | News

Washington state backs AI-driven cancer diagnostics and other startup projects – GeekWire
« Older Entries
Next Entries »

Categories

  • Events (2)
  • News (23)
  • Press Release (9)
  • Contact
    © 2024 KAYOTHERA® — All Rights Reserved